Evidence map›Paper›PMID 32673593›Full record

Observational studyThe Lancet. Infectious diseases2020

Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study.

Mars Stone, Sonia Bakkour, Marion C Lanteri, Donald Brambilla, Graham Simmons, Roberta Bruhn, Zhanna Kaidarova, Tzong-Hae Lee, Jose Orlando Alsina, Phillip C Williamson and 6 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Case Report: PositiveFrontiers in pediatrics · 2025
    Article
  10. Article
  11. Article
  12. Sentinel Enhanced Dengue Surveillance System - Puerto Rico, 2012-2022.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2024
    Article
  13. Evidence of Ongoing Transmission of Zika Virus in Mérida, Mexico.The American journal of tropical medicine and hygiene · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Mars StoneVitalant Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA. Electronic address: mstone@vitalant.org.
Sonia BakkourVitalant Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Marion C LanteriVitalant Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA; Cerus Corporation, Concord, CA, USA.
Donald BrambillaRTI International, Rockville, MD, USA.
Graham SimmonsVitalant Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Roberta BruhnVitalant Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Zhanna KaidarovaVitalant Research Institute, San Francisco, CA, USA.
Tzong-Hae LeeVitalant Research Institute, San Francisco, CA, USA.
Jose Orlando AlsinaBanco de Sangre de Servicios Mutuos, Guaynabo, PR, USA.
Phillip C WilliamsonCreative Testing Solutions, Tempe, AZ, USA.
Susan A GalelRoche Molecular Systems, Pleasanton, CA, USA.
Lisa L PateRoche Molecular Systems, Pleasanton, CA, USA.
Jeffrey M LinnenGrifols Diagnostic Solutions, San Diego, CA, USA.
Steve KleinmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Victoria, BC, Canada.
Michael P BuschVitalant Research Institute, San Francisco, CA, USA; Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
NHLBI Recipient Epidemiology Donor Evaluation Study REDS-III Program
University of California, San Francisco · USVitalant · USMaterials Systems (United States) · USPacific Research Institute · USGrifols (United States) · USRTI International · USUniversity of British Columbia · CA

Funding

NHLBI NIH HHS HHSN268201100001IWHI NIH HHS HHSN268201100001C
6 · The paper itself

Abstract

backgroundCharacterisation of the dynamics of Zika virus persistence following acute infection is needed to inform blood donor and diagnostic testing policies and understand the natural history of Zika virus infection. We aimed to characterise the natural history, persistence, and clinical outcomes of Zika virus infection through a prospective study in initially asymptomatic Zika virus RNA-positive blood donors.

methodsZika virus-infected blood donors identified through Zika virus nucleic acid amplification test (NAAT) screening at three blood collection organisations in the USA were enrolled into a 1-year follow-up study, with blood and body fluid samples and detailed symptom data collected at up to seven visits. All samples were tested for Zika virus RNA by real-time PCR (rtPCR); follow-up plasma, whole blood, and urine were also tested by replicate NAAT. Plasma was tested for flavivirus-specific IgM and IgG by ELISA. Zika virus RNA persistence for each assay or sample type and plasma antibody persistence from estimated date of plasma NAAT-detectable infection were calculated from follow-up data using survival statistical methods.

findingsBetween July 6, 2016 and March 7, 2017, we enrolled 53 participants. From the estimated date of plasma NAAT-detectable infection, Zika virus RNA was detectable in plasma for 9·9 days (95% CI 8·1-12·0), in red blood cells for 95·4 days (62·8-129·1), and in whole blood for 73·5 days (39·8-107·5). Replicate NAATs (one or more of eight replicates positive) extended detection of Zika virus RNA in plasma to 34·8 days (19·9-56·2) and in whole blood (at least one of two tests positive) to 104·8 days (76·7-129·9). Urine was rtPCR reactive up to 14·5 days (10·5-20·3) and saliva up to 26·4 days (19·7-38·7). Zika virus IgM persisted for 237·7 days (128·7-459·5) from estimated time since plasma NAAT-detectable infection. Zika virus RNA fell below detectable limits more rapidly in the saliva of participants with pre-existing dengue virus IgG than in those without. Of 25 donors identified pre-seroconversion with symptom data at the first or second study visit, 16 (64%) developed multiple Zika virus-related symptoms after asymptomatic index donations, compared with nine (36%) of 25 donors detected after seroconversion.

interpretationDetermination of viral marker persistence is enhanced by follow-up of blood donors who are pre-symptomatic or asymptomatic, Zika virus RNA-positive, and antibody negative. Zika virus RNA persists in red blood cells for several months following clearance from plasma and body fluids, and replicate, highly sensitive NAATs extend RNA detection in all compartments. Whole blood testing can extend detection of acute infection for diagnostics and monitoring of pregnant women, sexual partners, and travellers.

fundingNational Heart, Lung, and Blood Institute, Biomedical Advanced Research and Development Authority.

Indexed as

Zika VirusAntibodies, ViralHumansImmunoglobulin MProspective StudiesRNA, ViralZika Virus InfectionAntibodies, ViralImmunoglobulin MRNA, Viral

Identifiers

PMID32673593
PMCPMC10029720
OpenAlexW3041605310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.